Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: Preliminary observational data in an office-based setting

Clinical Drug Investigation

Volumn 30, Issue SUPPL. 1, 2010, Pages 33-39

  Amato, Patrizia ^a  

^a SerT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; DRUG COMBINATION; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANXIETY; ARTICLE; CONSTIPATION; CONTROLLED STUDY; COST CONTROL; COST OF ILLNESS; DIARRHEA; DRUG EFFICACY; DRUG HALF LIFE; DRUG MISUSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; FEMALE; FOLLOW UP; HEADACHE; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; INSOMNIA; ITALY; LIBIDO; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBSERVATIONAL STUDY; OPIATE ADDICTION; OUTPATIENT CARE; PATIENT COUNSELING; PATIENT SATISFACTION; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHINITIS; SIDE EFFECT; SWEATING; TREATMENT DURATION; VOMITING; WITHDRAWAL SYNDROME; ADDICTION; AMBULATORY CARE; COST BENEFIT ANALYSIS; COUNSELING; DIAGNOSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG COST; ECONOMICS; INTRAVENOUS DRUG ADMINISTRATION; OPIOID-RELATED DISORDERS; PREVENTION AND CONTROL; PSYCHOLOGY; SUBLINGUAL DRUG ADMINISTRATION; SUBSTANCE ABUSE; SUBSTANCE WITHDRAWAL SYNDROME; TIME; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BEHAVIOR, ADDICTIVE; BUPRENORPHINE; COST-BENEFIT ANALYSIS; COUNSELING; DELIVERY OF HEALTH CARE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG COSTS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; ITALY; MALE; NALOXONE; NARCOTIC ANTAGONISTS; OFFICE VISITS; OPIOID-RELATED DISORDERS; PATIENT SATISFACTION; QUALITY OF HEALTH CARE; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 77952395350     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536060-000000000-00000     Document Type: Article

References (26)

1. Bickel WK, Stitzer ML, Bigelow GE, et al. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988 Oct; 247 (1): 47-53.
2. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend 2003 May 21; 70 (2 Suppl.): S59-77.
3. Prescribing Information - Methadone (Italy). [cited 2009 14 Nov]; Available from: http://www.pharmamarketing.it/cont/020ser/050pro/default.asp? method=Mostra-Contenuto&id-cont=61641.
4. Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007 Dec 10; 167 (22): 2469-2475.
5. Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 Apr 17; 88 (1): 75-78.
6. Best SE, Oliveto AH, Kosten TR. Opioid addiction: recent advances in detoxification and maintenance therapy. CNS Drugs 1996; 6 (4): 301-314.
7. Chapleo CB, Walter DS. The buprenorphine-naloxone combination product. Res Clin Forums 1997; 19 (2): 55-58.
8. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20 (9): 697-712.
9. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003 Sep 4; 349 (10): 949-958.
10. Drug Addiction Treatment Act. 42 USC§3502a; 2000.
11. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict 2004; 13 (Suppl. 1): S42-66.
12. Gunderson EW, Fiellin DA. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches? CNS Drugs 2008; 22 (2): 99-111.
13. Helm S, Trescot AM, Colson J, et al. Opioid antagonists, partial agonists, and agonists/antagonists: the role of office-based detoxification. Pain Physician 2008 Mar-Apr; 11 (2): 225-235.
14. Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend 2003 May 21; 70 (2 Suppl.): S79-85.
15. Zung WWK. A rating instrument for anxiety disorders. Psychosomatics 1971; 12: 371-379.
16. Zung WWK. A self-rating depression scale. Arch Gen Psychiatry 1965; 12: 63-70.
17. Simojoki K, Vorma H, Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Subst Abuse Treat Prev Policy 2008; 3: 16.
18. Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002; 28 (2): 231-241.
19. Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006 Jul 27; 355 (4): 365-374.
20. O'Connor PG, Oliveto AH, Shi JM, et al. A pilot study of primary-care-based buprenorphine maintenance for heroin dependence. Am J Drug Alcohol Abuse 1996 Nov; 22 (4): 523-531.
21. Resnick RB, Galanter M, Resnick E, et al. Buprenorphine treatment of heroin dependence (detoxification and maintenance) in a private practice setting. J Addict Dis 2001; 20 (2): 75-83.
22. Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med 2005 Nov; 20 (11): 1038-1041.
23. Bell J, Byron G, Gibson A, et al. A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 2004 Sep; 23 (3): 311-317.
24. O'Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998 Aug; 105 (2): 100-105.
25. Ortner R, Jagsch R, Schindler SD, et al. Buprenorphine maintenance: office-based treatment with addiction clinic support. Eur Addict Res 2004; 10 (3): 105-111.
26. Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and cost-effectiveness of observed versus unobserved administration of buprenorphine-naloxone for heroin dependence. Addiction 2007 Dec; 102 (12): 1899-1907.